Ionis Pharmaceuticals

#Neurology #Cardiology #Metabolic #Rare Diseases

Ionis Pharmaceuticals is a leader in RNA-targeted therapeutics, discovering and developing antisense oligonucleotide (ASO) drugs for serious diseases.

Company Info

Sector:Biopharmaceutical

Headquarters:Carlsbad, California, United States

Founded:1989

Website:www.ionispharma.com/

Upcoming Milestones & Key Dates

2026-Q4

Regulatory

Olezarsen FDA decision expected

Clinical Development Pipeline

Olezarsen

Target: ApoC-III

Familial chylomicronemia syndrome

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Donidalorsen

Target: PKLR

Hereditary angioedema

Preclinical

Phase 1

Phase 2

Phase 3

Approved

IONIS-MAPTRx

Target: MAPT

Alzheimer's disease

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Ionis wins FDA label expansion for potential blockbuster triglycerides indication ↗

Ionis wins FDA label expansion for potential blockbuster triglycerides indication — Endpoints News coverage of biopharma industry developments.

Leadership Team

Brett Monia

Chief Executive Officer

Elizabeth Hougen

Chief Financial Officer

C. Frank Bennett

Chief Scientific Officer

Careers & Job Openings

See all open roles

Apply Now →